Anti-tuberculosis special Chinese patent medicine - Qibei Capsules

Abstract

The invention relates to a special Chinese patent medicine for resisting phthisis-astragalus fritillaria capsules, which is prepared from 120-150g of radix astragali, 20-50g of aweto, 80-100g of gecko, 50-80g of fritillaria cirrhosa, 50-70g of stemona, 48-70g of lily root, 30-50g of ginkgo, 56-76g of hyacinth bletilla, 120-150g of coix seed, 20-50g of radix glehniae, 80-102g of radix rehmanniae preparata, 60-85g of radix ophiopogonis, 55-75g of tuckahoe, 80-130g of taraxacum and 60-75g of oyster. The Chinese patent medicine not only can be made into capsules according to the formula of the composition, but also can be made into tablets, pills, powder and oral liquids according to the formula of the composition. The capsules are prepared from Chinese medicinal herbs, and can treat tuberculosis (mainly phthisis) by utilizing the comprehensive conditioning actions of the Chinese medicinal herbs; the capsules can not generate toxic or side effect, and also can not generate drug resistance, and the effective rate is up to more than 95%; and the capsules can be combined with other antituberculosis medicines to enhance the curative effect (especially for drug-resistant strain infected cases), and can also be independently used for patients who are allergic to western antituberculosis medicines or can not stand for the toxic or side effect.

Description

Technical field [0001] The invention relates to a special Chinese patent medicine for anti-tuberculosis-Qibei capsules, in particular to a special effect medicine for the treatment of pulmonary tuberculosis, belonging to the field of traditional Chinese medicine. Background technique [0002] Pulmonary tuberculosis, commonly known as "tuberculosis", is a chronic infectious disease caused by Mycobacterium tuberculosis infecting the lungs. It is the most common type of tuberculosis. The pathological features of pulmonary tuberculosis are tuberculosis nodules, cheese necrosis, and cavities in the lungs. Mycobacterium tuberculosis is mainly spread through the respiratory tract. It is usually caused by inhalation of tuberculosis-containing droplets that are emitted when a tuberculosis patient coughs, sneezes, or speaks loudly. The human body does not necessarily get sick after infection with Mycobacterium tuberculosis, and a small number of people get sick when their resistance drops...

AI Technical Summary

Problems solved by technology

Although antibacterial drugs have a certain effect on the treatment of pulmonary tuberculosis, due to insufficient dosage or long-term blind use of antibacterial drugs, conditions are provided for the development of drug resistance of Mycobacterium tuberculosis. Some have a bactericidal effect, and even make the drug completely lose its efficacy; and once a patient's tuberculosis bacillus develops drug resistance, this drug-resistant strain will also spread to other tuberculosis patients

In this case, tuberculosis patients often require a second round of treatment with stronger drugs that can cost thousands of dollars per course

In addition, long-term use of antibacterial drugs will lead to the harmonization of human flora and secondary infection, and have certain toxic and side effects on the patient's hearing, liver, kidney, and gastrointestinal functions.

In the field of traditional Chinese medicine, so far, there is no effective Chinese medicine preparation for the treatment of tuberculosis among the newly approved Chinese medicine preparations in the country.